

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

18th March 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani

### **Notice of the First Patient Dosed in the Initial Expansion Cohort of rogocekib**

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) today announced that it has confirmed that the first patient has been dosed in the Initial Expansion Cohort of the ongoing Phase 1/2 clinical trial of rogocekib in the United States (hereinafter, the “Study”).

Following the recommendation of the Study’s Safety Review Committee, the Company decided to initiate the Initial Expansion Cohort and promptly notified all participating clinical sites of this decision. Multiple sites soon identified several potential candidates, and screening procedures toward patient enrollment were conducted as planned in accordance with the Study protocol. Through these processes, the first patient in the Expansion Cohort has now received the initial dose of study treatment.

Chordia remains committed to advancing the development program with the highest priority placed on patient safety. We will continue to provide timely updates as developments warrant.

For details of the Study, please refer to the following website:  
[clinicaltrials.gov \(NCT05732103\)](https://clinicaltrials.gov/NCT05732103).

#### **About Chordia Therapeutics**

Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website

<https://www.chorditherapeutics.com/en/>.